Last reviewed · How we verify
lymphocyte immune globulin
lymphocyte immune globulin is a Small molecule drug developed by Cedars-Sinai Medical Center. It is currently in Phase 1 development. Also known as: ATGAM.
At a glance
| Generic name | lymphocyte immune globulin |
|---|---|
| Also known as | ATGAM |
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Constipation
- Anaemia
- Oedema peripheral
- Nausea
- Asthenia
- Urinary tract infection
- Hypertension
- Pyrexia
- Decreased appetite
- Cough
- Vomiting
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lymphocyte immune globulin CI brief — competitive landscape report
- lymphocyte immune globulin updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI
Frequently asked questions about lymphocyte immune globulin
What is lymphocyte immune globulin?
lymphocyte immune globulin is a Small molecule drug developed by Cedars-Sinai Medical Center.
Who makes lymphocyte immune globulin?
lymphocyte immune globulin is developed by Cedars-Sinai Medical Center (see full Cedars-Sinai Medical Center pipeline at /company/cedars-sinai-medical-center).
Is lymphocyte immune globulin also known as anything else?
lymphocyte immune globulin is also known as ATGAM.
What development phase is lymphocyte immune globulin in?
lymphocyte immune globulin is in Phase 1.
What are the side effects of lymphocyte immune globulin?
Common side effects of lymphocyte immune globulin include Diarrhoea, Constipation, Anaemia, Oedema peripheral, Nausea, Asthenia.
Related
- Manufacturer: Cedars-Sinai Medical Center — full pipeline
- Also known as: ATGAM
- Compare: lymphocyte immune globulin vs similar drugs
- Pricing: lymphocyte immune globulin cost, discount & access